The horizontal axis represents time points: Baseline and Month 12. The vertical axis represents counts per minute (cpm) on a logarithmic scale ranging from 10 to 1,000,000. The plot includes two vertical box plots. The baseline box plot shows a median value around 3000 cpm, with the lower quartile around 850 cpm and the upper quartile around 22,271 cpm. The whiskers extend from approximately 100 cpm to 100,000 cpm, with several outliers below 100 cpm and above 100,000 cpm. The Month 12 box plot shows a median value around 143,485 cpm, with the lower quartile around 99,854 cpm and the upper quartile around 206,169 cpm. The whiskers extend from approximately 50,000 cpm to 300,000 cpm, with fewer outliers compared to the baseline. Red dots represent participants with PHA responses less than 5000 cpm at baseline, while black dots represent participants with PHA responses greater than 5000 cpm at baseline. There is a significant increase in median PHA response from baseline to 12 months post-CTTI, as indicated by the p-value of less than 0.0001.
Comparison of PHA response at baseline and 12 mo after CTTI. Median PHA (cpm) response among participants at baseline versus 12 mo after CTTI. Comparison by Wilcoxon-matched pairs signed-rank test. There is a significant increase in median PHA response from baseline (pre-CTTI) to 12 mo after CTTI. Red dots represent participants that had PHA responses <5,000 cpm at baseline, prior to CTTI, while black dots represent participants that had PHA responses >5,000 at baseline. 12-mo PHA response data are excluded for three participants who received alemtuzumab after CTTI as treatment for autoimmunity. PHA proliferation responses were not available in four participants at 12 mo after CTTI. Median (Q1; Q3) PHA response (cpm) for baseline and 12 mo after CTTI are 2,988 (849; 22,271) and 143,485 (99,854; 206,169), respectively.